RC Fornax, Blencowe Resources, Oxford BioMedica, Pantheon International - Small Cap Snapshot

Why It Matters

These developments signal shifting capital flows in defence, critical minerals and biotech, influencing investor risk‑return assessments, while Pantheon’s actions highlight how currency moves affect NAV‑based trusts.

Key Takeaways

• RC Fornax targets seven UK defence frameworks, boosting pipeline.
• Blencowe expects first JORC resource by Q1 2026.
• Oxford BioMedica shares down 9% amid EQT takeover speculation.
• Pantheon International NAV fell 1.4% due to sterling strength.
• Pantheon repurchased shares at discount, retains £291m facility headroom.

Pulse Analysis

The UK’s defence budget overhaul is creating a fertile landscape for niche contractors like RC Fornax. By pursuing seven separate procurement frameworks and securing three advanced‑stage agreements, the firm is diversifying its revenue streams beyond traditional aerospace contracts. Its recent £2.1 million capital raise, coupled with £4.5 million of FY26 sales visibility, underscores investor confidence in a sector where sovereign spending is increasingly earmarked for next‑generation capabilities and space‑related projects.

In the critical minerals arena, Blencowe Resources’ latest drilling at the Iyan deposit in Uganda adds depth to its graphite portfolio, a metal essential for battery anodes and emerging energy storage solutions. The company’s timeline for a maiden JORC‑compliant resource by the first quarter of 2026 positions it to capture early‑stage demand as electric‑vehicle supply chains seek diversified, low‑cost sources. Uganda’s stable mining policy and the project's near‑surface nature reduce development risk, potentially accelerating cash‑flow generation for investors focused on the green transition.

Oxford BioMedica’s 9% share decline, despite meeting revenue guidance, reflects market anticipation of a possible EQT acquisition—a move that could unlock value through scale and platform synergies in gene‑therapy manufacturing. Meanwhile, Pantheon International’s NAV dip illustrates how currency fluctuations can erode asset valuations in global investment trusts, even when underlying portfolio performance remains solid. The trust’s decision to buy back shares at a wide discount and maintain £291 million of facility headroom demonstrates disciplined capital management, offering a buffer against market volatility and preserving shareholder upside.

Original Description

RC Fornax PLC (AIM:RCFX) says it’s well placed as the UK reshapes defence spending. It’s bidding across seven frameworks and has three major agreements in advanced talks. The group joined Aurora’s Evolve network in January and won a UK public sector space contract. A December fundraise added £2.1 million, with £4.5 million in firm FY26 sales visibility.

Blencowe Resources PLC (LSE:BRES) reported more thick, near-surface graphite hits at the Iyan deposit in Uganda. A maiden JORC resource is now expected in the first quarter of 2026.

Oxford BioMedica PLC (LSE:OXB) shares fell 9% despite revenue hitting the top of guidance. Investors are waiting on a possible takeover move from EQT before a looming deadline.

Pantheon International PLC (LSE:PIN, FRA:PAA0) saw NAV dip 1.4% in January as sterling strength weighed, despite a positive performance from its underlying portfolio. The trust bought back shares at a wide discount and still has £291 million in facility headroom.

Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.